Document is current
Any future updates will be listed below
-
Authors
Capasso, Giovambattista https://orcid.org/0000-0003-3469-8614
Franssen, Casper F. M. https://orcid.org/0000-0003-1004-9994
Perna, Alessandra F. https://orcid.org/0000-0003-4048-9392
Massy, Ziad A.
Menzies, Robert I.
Zoccali, Carmine https://orcid.org/0000-0002-6616-1996
Tessitore, Alessandro
Nedergaard, Maiken https://orcid.org/0000-0001-6502-6031
Okusa, Mark D. https://orcid.org/0000-0002-0801-0532
Ortiz, Alberto https://orcid.org/0000-0002-9805-9523
Wagner, Carsten A. https://orcid.org/0000-0002-9874-8898
Unwin, Robert J. https://orcid.org/0000-0001-7839-6031
- License Information
-
More Information
Article History
Accepted: 4 April 2025
First Online: 25 April 2025
Competing interests
: A.O. has received grants from Sanofi, and consultancy or speaker fees or travel support from Adviccene, Alexion, Astellas, Astrazeneca, Amicus, Amgen, Bioporto, Boehringer Ingelheim, Esteve, Fresenius Medical Care, GSK, Bayer, Sanofi-Genzyme, Sobi, Menarini, Mundipharma, Kyowa Kirin, Lilly, Freeline, Idorsia, Chiesi, Otsuka, Novo-Nordisk, Sysmex and Vifor Fresenius Medical Care Renal Pharma and Spafarma; is the Director of the Catedra UAM-Astrazeneca of chronic kidney disease and electrolytes; and owns Telara Farma stock. C.F.M.F. received research grants from Baxter, Fresenius and Sandoz; and is on the Advisory board of Pharvaris. C.A.W. reports honoraria from Kyowa Kirin and Medice; and scientific collaboration with Bayer AG. M.D.O. is on the scientific advisory board of AstraZeneca. R.I.M. is currently employed as Senior Director Bioscience Renal, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden. Z.A.M. reports grants from Amgen, Baxter, Fresenius Medical Care, GlaxoSmithKline, Merck Sharp and Dohme-Chibret, Genzyme/Sanofi, Lilly, Otsuka and Boehringer Ingelheim; Government support for CKD REIN PROJECT AND EXPERIMENTAL PROJECTS; and payment or honoraria for lectures and presentations to charities from AstraZeneca, GSK and Boehringer Ingelheim. R.J.U. is currently employed as a Chief Scientist by AstraZeneca Biopharmaceuticals R&D, Translational Science and Experimental Medicine (TSEM), and Early Cardiovascular, Renal and Metabolism (eCVRM), Cambridge, UK. M.N. is a paid consultant for CNS2 for unrelated work. The other authors declare no competing interests.
